Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18411284 | PREFUSION-STABILIZED HMPV F PROTEINS | January 2024 | April 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18454526 | LAMP Constructs | August 2023 | June 2024 | Allow | 9 | 1 | 1 | No | No |
| 18335893 | ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES | June 2023 | March 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18296771 | PREFUSION-STABILIZED HMPV F PROTEINS | April 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18186064 | POLYOMAVIRUS NEUTRALIZING ANTIBODIES | March 2023 | April 2024 | Allow | 13 | 0 | 0 | No | No |
| 18185153 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18115066 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES | February 2023 | April 2024 | Allow | 14 | 1 | 0 | No | No |
| 18108248 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | February 2023 | January 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18100732 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | January 2023 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18157534 | NUCLEOTIDE SEQUENCE EXPRESSING AN EXOSOME-ANCHORING PROTEIN FOR USE AS VACCINE | January 2023 | August 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18069058 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | December 2022 | June 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18067940 | ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 18001395 | RAPID LOW-COST DETECTION OF SARS-COV-2 USING ISOTHERMAL AMPLIFICATION AND SENSING METHODS | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18060799 | RESTRICTIVE INVERTED TERMINAL REPEATS FOR VIRAL VECTORS | December 2022 | November 2023 | Allow | 11 | 0 | 0 | No | No |
| 18046817 | MATERIALS AND METHODS RELATING TO IMMUNOGENIC EPITOPES FROM HUMAN PAPILLOMAVIRUS | October 2022 | June 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17894945 | FORMULATION OF A PEPTIDE VACCINE | August 2022 | April 2024 | Allow | 20 | 2 | 0 | No | No |
| 17887545 | Stable, Spray Dried, Immunogenic, Viral Compositions | August 2022 | July 2024 | Abandon | 23 | 2 | 0 | No | No |
| 17817591 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | August 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17875298 | METHODS OF PREDICTING SUSCEPTIBILITY TO INFECTIOUS DISEASE AND RELATED METHODS OF TREATMENT | July 2022 | May 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17868144 | FREEZE DRIED VIRAL NANOPARTICLE CONSTRUCTS | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17812896 | COMPOSITIONS COMPRISING CURONS AND USES THEREOF | July 2022 | April 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17812492 | Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof | July 2022 | April 2024 | Abandon | 21 | 2 | 0 | No | No |
| 17838662 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17833133 | Composition Comprising PIC For Treatment Of Cancer | June 2022 | October 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17664717 | IMMUNOSTIMULATORY METHOD | May 2022 | May 2023 | Allow | 12 | 1 | 0 | No | No |
| 17719779 | Immunogenic Human Rhinovirus (HRV) Composition | April 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17702231 | E1E2 HCV VACCINES AND METHODS OF USE | March 2022 | December 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17694264 | ASSOCIATION BETWEEN INTEGRATION OF HIGH-RISK HPV GENOMES DETECTED BY MOLECULAR COMBING AND THE SEVERITY AND/OR CLINICAL OUTCOME OF CERVICAL LESIONS | March 2022 | December 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17689908 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | March 2022 | January 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 17687732 | MHC CLASS IA OPEN CONFORMERS | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17681342 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | February 2022 | March 2024 | Allow | 24 | 2 | 0 | No | No |
| 17680813 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES | February 2022 | April 2023 | Allow | 13 | 0 | 1 | No | No |
| 17665285 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE MULTI-TARGETED ANTIGENS | February 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17587953 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | January 2022 | August 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17581655 | ENGINEERED HEPATITIS B CORE POLYPEPTIDE | January 2022 | September 2023 | Abandon | 20 | 1 | 1 | Yes | No |
| 17559391 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | December 2021 | June 2023 | Allow | 18 | 1 | 1 | No | No |
| 17557886 | IMMUNOSWITCH NANOPARTICLES FOR REPROGRAMMED T CELL RESPONSES | December 2021 | January 2024 | Allow | 25 | 2 | 0 | No | No |
| 17556816 | COMPOSITIONS OF INFLUENZA HEMAGGLUTININ WITH HETEROLOGOUS EPITOPES AND/OR ALTERED MATURATION CLEAVAGE SITES AND METHODS OF USE THEREOF | December 2021 | August 2023 | Abandon | 20 | 1 | 0 | Yes | No |
| 17550272 | VACCINES AGAINST GENITAL HERPES SIMPLEX INFECTIONS | December 2021 | July 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17596061 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND SMALL MOLECULE PDL1 OR PD1 INHIBITOR | December 2021 | April 2024 | Abandon | 28 | 2 | 0 | Yes | No |
| 17532177 | HPV VACCINE | November 2021 | April 2024 | Allow | 29 | 3 | 0 | No | No |
| 17521196 | METHODS OF IDENTIFYING PATIENTS AS HAVING AN INCREASED LIKELIHOOD OF HAVING A HUMAN PAPILLOMA VIRUS (HPV)-ASSOCIATED CANCER OR RECURRENCE OF AN HPV-ASSOCIATED CANCER | November 2021 | June 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17514857 | LAMP Constructs | October 2021 | June 2023 | Allow | 20 | 1 | 1 | No | No |
| 17514724 | METHODS FOR GENERATING THERAPEUTIC DELIVERY PLATFORMS | October 2021 | October 2023 | Allow | 24 | 1 | 1 | No | No |
| 17502910 | Polyomavirus Neutralizing Antibodies | October 2021 | December 2022 | Allow | 14 | 0 | 0 | No | No |
| 17492238 | IN VITRO HBV CORE PROTEIN ASSAY | October 2021 | January 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17484476 | ATTB CELL LINE, TRANSGENIC CELL LINES DERIVED THEREFROM, AND METHODS OF MAKING THE SAME | September 2021 | January 2024 | Allow | 28 | 2 | 1 | No | No |
| 17472003 | MERS-CoV Vaccine | September 2021 | June 2023 | Allow | 21 | 1 | 0 | No | No |
| 17435687 | METHOD FOR SEQUENCING A DIRECT REPEAT | September 2021 | August 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17410453 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | August 2021 | May 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17430474 | Method for Extracting Hepatitis A Virus (HAV) Antigen from Cell Culture | August 2021 | June 2022 | Allow | 10 | 1 | 0 | No | No |
| 17399821 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDS | August 2021 | May 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17396579 | SPATIAL SEQUENCING | August 2021 | July 2022 | Allow | 11 | 3 | 0 | No | No |
| 17384589 | HPV-SPECIFIC BINDING MOLECULES | July 2021 | June 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17372927 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | July 2021 | February 2022 | Allow | 8 | 1 | 0 | No | No |
| 17373093 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17373130 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17303063 | ULTRA-SENSITIVE, FAST, PLASMONIC-FLUOR ENHANCED ASSAY FOR SARS-COV-2 IMMUNE RESPONSE | May 2021 | May 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17320944 | Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same | May 2021 | April 2023 | Allow | 23 | 1 | 0 | No | No |
| 17319081 | NEUTRALIZING ANTIBODY TESTING AND TREATMENT | May 2021 | June 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17240991 | METHODS OF PREDICTING SUSCEPTIBILITY TO INFECTIOUS DISEASE AND RELATED METHODS OF TREATMENT | April 2021 | April 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17236561 | METHODS FOR GENERATING THERAPEUTIC DELIVERY PLATFORMS | April 2021 | September 2021 | Allow | 5 | 1 | 0 | No | No |
| 17301626 | IMMUNE COMPLEX | April 2021 | February 2023 | Allow | 22 | 1 | 0 | No | No |
| 17275967 | METHOD FOR PRODUCING AN ANTITUMORAL ARENAVIRUS AS WELL AS ARENAVIRUS MUTANTS | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17194779 | NOVEL VACCINES AGAINST HPV AND HPV-RELATED DISEASES | March 2021 | March 2023 | Allow | 24 | 1 | 0 | No | No |
| 17168461 | GENERATING HPV ANTIGEN-SPECIFIC CELLS FROM A NAIVE T CELL POPULATION | February 2021 | January 2024 | Allow | 36 | 2 | 1 | No | No |
| 17156908 | METHODS AND COMPOSITIONS OF CHEMICALLY MODIFIED PHAGE LIBRARIES | January 2021 | March 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17152149 | GENERATING HPV ANTIGEN-SPECIFIC CELLS FROM A NAIVE T CELL POPULATION | January 2021 | January 2023 | Allow | 24 | 1 | 0 | No | No |
| 17142486 | ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS | January 2021 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17141704 | Vaccines For Human Papilloma Virus And Methods For Using The Same | January 2021 | May 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17113570 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS | December 2020 | June 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 15734715 | Mutant of L1 Protein of Human Papillomavirus Type 39 | December 2020 | April 2022 | Allow | 16 | 1 | 0 | Yes | No |
| 15734750 | Mutant of L1 Protein of Human Papillomavirus Type 66 | December 2020 | May 2022 | Allow | 17 | 1 | 0 | No | No |
| 17057153 | COMPOSITIONS AND METHODS FOR TREATING RSV-INFECTIONS | November 2020 | October 2023 | Allow | 35 | 0 | 0 | Yes | No |
| 16953109 | RESTRICTIVE INVERTED TERMINAL REPEATS FOR VIRAL VECTORS | November 2020 | September 2022 | Allow | 22 | 0 | 0 | No | No |
| 17099633 | COMPOSITIONS OF AND METHODS FOR IN VITRO VIRAL GENOME ENGINEERING | November 2020 | October 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 17055416 | COMPOSITIONS AND METHODS FOR DELIVERY OF AAV | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17084841 | CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | October 2020 | January 2024 | Abandon | 39 | 2 | 1 | No | No |
| 16949331 | CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH BEVACIZUMAB | October 2020 | March 2023 | Abandon | 28 | 2 | 0 | No | No |
| 17074358 | RECOMBINANT VIRAL VECTORS | October 2020 | September 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 17068087 | METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN LESION USING A VACCINE | October 2020 | August 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 17045753 | HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT | October 2020 | February 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17061146 | ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES | October 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 17060944 | RSV F Protein Mutants | October 2020 | April 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17030737 | Attenuated Strains of Oncolytic Rhabdovirus and Uses Thereof in Tumor Treatment | September 2020 | May 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17020670 | Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells | September 2020 | July 2023 | Abandon | 34 | 1 | 1 | Yes | No |
| 17015955 | SEROLOGIC TEST FOR THERAPY CONTROL OF HPV16 POSITIVE CARCINOMA | September 2020 | July 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 17016264 | TREATMENT AND PREVENTION OF PLANTAR WARTS | September 2020 | July 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16978570 | HEPATITIS B VACCINES AND USES OF THE SAME | September 2020 | August 2022 | Allow | 24 | 1 | 1 | No | No |
| 17011990 | BROAD RANGE GENE AND GENOTYPE PAPILLOMAVIRUS TRANSCRIPTOME AS A BIOMARKER OF PAPILLOMAVIRUS-ASSOCIATED CANCER STAGES | September 2020 | August 2022 | Allow | 23 | 1 | 0 | No | No |
| 16975602 | SPLIT-IMMUNOTOXINS FOR BOOSTING ONCOLYTIC VIRUS TOXICITY | August 2020 | March 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 16996433 | VACCINE COMPOSITION | August 2020 | August 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16995647 | SYSTEMS AND METHODS FOR GENERATING IMMUNE RESPONSES IN SUBJECTS USING MICROCHANNEL DELIVERY DEVICES | August 2020 | August 2021 | Allow | 12 | 2 | 0 | Yes | No |
| 16988659 | VLP Stabilized Vaccine Compositions | August 2020 | December 2023 | Allow | 40 | 5 | 0 | Yes | No |
| 16966387 | Compositions and Methods for Promoting Immune Responses to Human Immunodeficiency Virus | July 2020 | October 2022 | Allow | 27 | 2 | 0 | No | No |
| 16931291 | IMMUNOGENIC RSV POLYPEPTIDES | July 2020 | June 2022 | Allow | 23 | 1 | 1 | No | No |
| 16961238 | IMMUNOGENIC COMPOSITION | July 2020 | August 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 16921253 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONS | July 2020 | June 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16921899 | DUCK HEPATITIS A VIRUS TYPE 3 MUTANT CH-P60-117C AND CONSTRUCTION THEREOF | July 2020 | April 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 16919356 | Stable, Spray Dried, Immunogenic, Viral Compositions | July 2020 | May 2022 | Allow | 22 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZOU, NIANXIANG.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZOU, NIANXIANG works in Art Unit 1648 and has examined 643 patent applications in our dataset. With an allowance rate of 63.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner ZOU, NIANXIANG's allowance rate of 63.0% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZOU, NIANXIANG receive 2.06 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ZOU, NIANXIANG is 25 months. This places the examiner in the 65% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +27.3% benefit to allowance rate for applications examined by ZOU, NIANXIANG. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.2% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 68.2% of appeals filed. This is in the 48% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 69.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.